The US CRAMS Market Outlook to 2018 - Driven by Ageing Population and Rise of Chronic Diseases
The industry research publication titled ‘The US CRAMS Market Outlook to 2018 – Driven by Ageing Population and Rise of Chronic Diseases’ presents a comprehensive analysis of market size by value of CRAMS services in the US. The report entails the market share analysis and company profiles of major players in the CRAMS industry. The future analysis and segmentation by drugs and devices and therapeutic areas have also been discussed in each of the sub-segment.
The US is the most developed and active market across the globe in the area of contract research and manufacturing services. The CRAMS industry in the US has proliferated across a wide spectrum of research and development services with rising demand from pharmaceutical, medical device and biotechnology companies. However despite considered as the premier destination for outsourcing contract research and manufacturing services initially, the industry in the recent years has faced stiff competition from low cost destinations such as India and China. The US CRAMS market has grown at a CAGR of 10.6% during 2007-2013 achieving a market size of USD ~ billion in 2018. The revenues for CMO market generated USD ~ billion in 2013 while that from CRO market reached USD ~ billion in 2013. The CMO market of US has majorly been driven by the solid dose category which contributed nearly ~% of the US CMO industry in 2011. A number of factors have contributed to the increased demand of contract research services in the country. Rising aged population has been the major underlying factor for the growth of contract research services in the country since the prevalence rate of chronic diseases has been found to be the highest in the ageing population. The US CRAMS industry is majorly driven by innovation and development in the drugs segment. The drugs industry comprised of 70.0% of the contribution of the CRAMS industry with a market size of USD ~ billion in 2013. Therapeutic areas such as oncology, central nervous system disorders, infectious and cardiovascular diseases are gaining additional importance due to rising number of cases in the country. Oncology had the largest share in the US CRAMS market with a share of ~% followed by cardiovascular diseases with a share of ~% in 2013. In the coming years, the US CMO market is expected to reach USD ~ billion by 2018 representing a growth of 7.5% during 2013-2018 and would be overtaken by the CRO segment.
The US CRAMS industry is expected to witness a steady growth rate of 11.9% during 2013-2018, to reach a market size of USD ~ billion in 2018. The government funding which has witnessed significant funding cutbacks due to economic downturn is expected to show improvement in the coming years, given the need for ground breaking clinical discoveries.
KEY TOPICS COVERED IN THE REPORT
The US is the most developed and active market across the globe in the area of contract research and manufacturing services. The CRAMS industry in the US has proliferated across a wide spectrum of research and development services with rising demand from pharmaceutical, medical device and biotechnology companies. However despite considered as the premier destination for outsourcing contract research and manufacturing services initially, the industry in the recent years has faced stiff competition from low cost destinations such as India and China. The US CRAMS market has grown at a CAGR of 10.6% during 2007-2013 achieving a market size of USD ~ billion in 2018. The revenues for CMO market generated USD ~ billion in 2013 while that from CRO market reached USD ~ billion in 2013. The CMO market of US has majorly been driven by the solid dose category which contributed nearly ~% of the US CMO industry in 2011. A number of factors have contributed to the increased demand of contract research services in the country. Rising aged population has been the major underlying factor for the growth of contract research services in the country since the prevalence rate of chronic diseases has been found to be the highest in the ageing population. The US CRAMS industry is majorly driven by innovation and development in the drugs segment. The drugs industry comprised of 70.0% of the contribution of the CRAMS industry with a market size of USD ~ billion in 2013. Therapeutic areas such as oncology, central nervous system disorders, infectious and cardiovascular diseases are gaining additional importance due to rising number of cases in the country. Oncology had the largest share in the US CRAMS market with a share of ~% followed by cardiovascular diseases with a share of ~% in 2013. In the coming years, the US CMO market is expected to reach USD ~ billion by 2018 representing a growth of 7.5% during 2013-2018 and would be overtaken by the CRO segment.
The US CRAMS industry is expected to witness a steady growth rate of 11.9% during 2013-2018, to reach a market size of USD ~ billion in 2018. The government funding which has witnessed significant funding cutbacks due to economic downturn is expected to show improvement in the coming years, given the need for ground breaking clinical discoveries.
KEY TOPICS COVERED IN THE REPORT
- The market size of the US CRAMS market in terms of value in the last years (2007 - 2013)
- The US CRAMS market segmentation by CMO and CRO service
- The US CRAMS market segmentation by Drugs and Devices
- The US CRAMS for Drugs Market Segmentation by Therapeutic Areas
- Trends and Developments in the CRAMS market in the US
- Government Rules and Regulations in the CRAMS market in the US
- Competitive landscape in CRAMS market of the US (such as Quintiles, Covance, Lonza, Parexel, Catalent and others )
- Future projections and macro economic factors of CRAMS market in the US.
1. THE US CRAMS MARKET INTRODUCTION AND SIZE, 2007-2013
2. THE US CRAMS MARKET SEGMENTATION
2.1. By CMO and CRO Market, 2007-2018
2.2. By Drugs and Devices Markets, 2007-2018
2.2.1. The US CRAMS for Drugs Market Segmentation by Therapeutic Classes, 2007-2018
3. MARKET SHARE OF MAJOR PLAYERS IN THE US CRAMS MARKET, 2013
4. COMPETITIVE LANDSCAPE OF MAJOR PLAYERS IN THE US CRAMS MARKET
5. GOVERNMENT REGULATIONS IN THE US CRAMS MARKET
6. TRENDS AND DEVELOPMENTS IN THE US CRAMS MARKET
Focus on Solid Dosage in Contract Manufacturing
Evolution of E-clinical trials
Expiration of Patented Drugs
Privatization of CROs
Strategic Alliances between Pharmaceutical Companies and CROs
Reduced Government Spending on Clinical Research
7. THE US CRAMS MARKET FUTURE OUTLOOK AND PROJECTIONS
8. MACRO ECONOMIC FACTORS AFFECTING THE US CRAMS MARKET
8.1. Ageing Population, 2007-2018
8.2. The US Health Expenditure, 2007-2018
8.3. Gross Domestic Product, 2007-2018
8.4. The US Pharmaceutical Companies Domestic R&D Expenditure, 2007-2018
8.5. Personal Disposable Income, 2007-2018
9. APPENDIX
9.1. Market Definitions
9.2. Abbreviations
9.3. Research Methodology
Data Collection Methods
Approach
Variables (Dependent and Independent)
Multi Factor Based Sensitivity Model
Final Conclusion
9.4. Disclaimer
2. THE US CRAMS MARKET SEGMENTATION
2.1. By CMO and CRO Market, 2007-2018
2.2. By Drugs and Devices Markets, 2007-2018
2.2.1. The US CRAMS for Drugs Market Segmentation by Therapeutic Classes, 2007-2018
3. MARKET SHARE OF MAJOR PLAYERS IN THE US CRAMS MARKET, 2013
4. COMPETITIVE LANDSCAPE OF MAJOR PLAYERS IN THE US CRAMS MARKET
5. GOVERNMENT REGULATIONS IN THE US CRAMS MARKET
6. TRENDS AND DEVELOPMENTS IN THE US CRAMS MARKET
Focus on Solid Dosage in Contract Manufacturing
Evolution of E-clinical trials
Expiration of Patented Drugs
Privatization of CROs
Strategic Alliances between Pharmaceutical Companies and CROs
Reduced Government Spending on Clinical Research
7. THE US CRAMS MARKET FUTURE OUTLOOK AND PROJECTIONS
8. MACRO ECONOMIC FACTORS AFFECTING THE US CRAMS MARKET
8.1. Ageing Population, 2007-2018
8.2. The US Health Expenditure, 2007-2018
8.3. Gross Domestic Product, 2007-2018
8.4. The US Pharmaceutical Companies Domestic R&D Expenditure, 2007-2018
8.5. Personal Disposable Income, 2007-2018
9. APPENDIX
9.1. Market Definitions
9.2. Abbreviations
9.3. Research Methodology
Data Collection Methods
Approach
Variables (Dependent and Independent)
Multi Factor Based Sensitivity Model
Final Conclusion
9.4. Disclaimer
LIST OF FIGURES
Figure 1: The US CRAMS Market Size on the Basis of Revenue in USD Billion, 2007-2013
Figure 2: The US CRAMS Market Segmentation by CMO and CRO on the Basis of Revenue Contribution in Percentage, 2007-2013
Figure 3: The US CRAMS Market Segmentation by Drugs and Devices on the Basis of Revenue Contribution in Percentage, 2007-2013
Figure 4: The US CRAMS Market Future Projections on the Basis of Revenue in USD Billion, 2014-2018
Figure 5: Aged Population in the US in Million, 2007-2018
Figure 6: The US Healthcare Expenditure in USD Billion, 2007-2018
Figure 7: Gross Domestic Product of GDP in the USD Billion, 2007-2018
Figure 8: R&D Expenditure of Pharmaceutical Companies in the US in USD Billion, 2007-2018
Figure 9: Personal Disposable Income in the US in USD Billion, 2007-2018
Figure 1: The US CRAMS Market Size on the Basis of Revenue in USD Billion, 2007-2013
Figure 2: The US CRAMS Market Segmentation by CMO and CRO on the Basis of Revenue Contribution in Percentage, 2007-2013
Figure 3: The US CRAMS Market Segmentation by Drugs and Devices on the Basis of Revenue Contribution in Percentage, 2007-2013
Figure 4: The US CRAMS Market Future Projections on the Basis of Revenue in USD Billion, 2014-2018
Figure 5: Aged Population in the US in Million, 2007-2018
Figure 6: The US Healthcare Expenditure in USD Billion, 2007-2018
Figure 7: Gross Domestic Product of GDP in the USD Billion, 2007-2018
Figure 8: R&D Expenditure of Pharmaceutical Companies in the US in USD Billion, 2007-2018
Figure 9: Personal Disposable Income in the US in USD Billion, 2007-2018
LIST OF TABLES
Table 1: The US CMO and CRO Market Size on the Basis of Revenue in USD Billion, 2007-2013
Table 2: The US CRAMS Market Segmentation by CMO and CRO on the Basis of Revenue Contribution in Percentage, 2014-2018
Table 3: The US CMO and CRO Market Future Projections on the Basis of Revenue in USD Billion, 2014-2018
Table 4: The US CRAMS Market Segmentation by Drugs and Devices on the Basis of Revenue in USD Million
Table 5: The US CRAMS Market Segmentation by Drugs and Devices on the Basis of Revenue Contribution in Percentage, 2014-2018
Table 6: The US Drugs and Devices CRAMS Market Future Projections on the Basis of Revenue in USD Billion, 2014-2018
Table 7: The US CRAMS for Drugs Market Segmentation by Therapeutic Areas on the Basis of Revenue Contribution in USD Billion, 2007-2013
Table 8: The US CRAMS for Drugs Market Segmentation by Therapeutic Areas on the Basis of Revenue Contribution in Percentage, 2007-2013
Table 9: The US CRAMS for Drugs Market Segmentation on the Basis of Revenue in Percentage, 2014-2018
Table 10: The US CRAMS for Drugs Market Future Projection on the Basis of Revenue in USD Billion, 2014-2018
Table 11: Number of Clinical Studies Performed in Different Therapeutic Areas in the US, 2007-2013
Table 12: Market Share of Major Players in the US CRAMS Market on the Basis of Revenue Contribution in Percentage, 2011-2013
Table 13: Revenue of Major Players in the US CRAMS Market in USD Million, 2011-2013
Table 14: Company Profiles of Major Players in the US CRAMS Market
Table 15: The US FDA Acts and Codes Governing the Drug Development Market
Table 16: List of Major Drugs Losing Patents in the US, 2013-2016
Table 17: The Major CROs in the US which were Privatized, 2011-2013
Table 18: Strategic Alliances between Pharmaceutical Companies and CROs in the US, 2012
Table 19: The US Fiscal Budgets and Funding to NIH, FY’2006- FY’2012
Table 20: Correlation Matrix for the US CRAMS Market
Table 21: Regression Coefficients Output
Table 1: The US CMO and CRO Market Size on the Basis of Revenue in USD Billion, 2007-2013
Table 2: The US CRAMS Market Segmentation by CMO and CRO on the Basis of Revenue Contribution in Percentage, 2014-2018
Table 3: The US CMO and CRO Market Future Projections on the Basis of Revenue in USD Billion, 2014-2018
Table 4: The US CRAMS Market Segmentation by Drugs and Devices on the Basis of Revenue in USD Million
Table 5: The US CRAMS Market Segmentation by Drugs and Devices on the Basis of Revenue Contribution in Percentage, 2014-2018
Table 6: The US Drugs and Devices CRAMS Market Future Projections on the Basis of Revenue in USD Billion, 2014-2018
Table 7: The US CRAMS for Drugs Market Segmentation by Therapeutic Areas on the Basis of Revenue Contribution in USD Billion, 2007-2013
Table 8: The US CRAMS for Drugs Market Segmentation by Therapeutic Areas on the Basis of Revenue Contribution in Percentage, 2007-2013
Table 9: The US CRAMS for Drugs Market Segmentation on the Basis of Revenue in Percentage, 2014-2018
Table 10: The US CRAMS for Drugs Market Future Projection on the Basis of Revenue in USD Billion, 2014-2018
Table 11: Number of Clinical Studies Performed in Different Therapeutic Areas in the US, 2007-2013
Table 12: Market Share of Major Players in the US CRAMS Market on the Basis of Revenue Contribution in Percentage, 2011-2013
Table 13: Revenue of Major Players in the US CRAMS Market in USD Million, 2011-2013
Table 14: Company Profiles of Major Players in the US CRAMS Market
Table 15: The US FDA Acts and Codes Governing the Drug Development Market
Table 16: List of Major Drugs Losing Patents in the US, 2013-2016
Table 17: The Major CROs in the US which were Privatized, 2011-2013
Table 18: Strategic Alliances between Pharmaceutical Companies and CROs in the US, 2012
Table 19: The US Fiscal Budgets and Funding to NIH, FY’2006- FY’2012
Table 20: Correlation Matrix for the US CRAMS Market
Table 21: Regression Coefficients Output
